Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Arun A. Azad"'
Autor:
Muhammad Ali, Kendrick Koo, David Chang, Phil Chan, Sheng F. Oon, Daniel Moon, Declan G. Murphy, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Arun A. Azad, Sarat Chander, Mark Shaw, Nicholas Hardcastle, Shankar Siva
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-9 (2024)
Abstract Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment for patients with primary renal cell carcinoma (RCC). However, its impact on renal function is unclear. This study aimed to evaluate incidence and clinical fa
Externí odkaz:
https://doaj.org/article/08cdee63f1d54833baeea559c883b2c1
Publikováno v:
Société Internationale d’Urologie Journal, Vol 4, Iss 4, Pp 273-286 (2023)
The treatment landscape for metastatic prostate cancer has undergone significant changes in recent years. The availability of next-generation imaging techniques and the emergence of novel therapies have led to earlier and more aggressive treatment ap
Externí odkaz:
https://doaj.org/article/2c800bbd860b4ec0a54a5ba6ffe8aab7
Autor:
Heidi Fettke, Chao Dai, Edmond M. Kwan, Tiantian Zheng, Pan Du, Nicole Ng, Patricia Bukczynska, Maria Docanto, Louise Kostos, Siavash Foroughi, Stephen Brown, Lisa-Jane K. Graham, Kate Mahon, Lisa G. Horvath, Shidong Jia, Manish Kohli, Arun A. Azad
Publikováno v:
EBioMedicine, Vol 95, Iss , Pp 104738- (2023)
Summary: Background: Genomic alterations in DNA damage response (DDR) genes are common in metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic events impact prognosis and/or treatment response is vital for optimisi
Externí odkaz:
https://doaj.org/article/868bde2315c940f2aff0e43052a1b905
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
[ 177 Lu]Lu-PSMA has recently been approved for use in the post-taxane, post-novel hormonal-agent setting in patients with metastatic castration-resistant prostate cancer. As a beta-emitting radioligand targeting prostate-specific membrane antigen (P
Externí odkaz:
https://doaj.org/article/de2a86168b5f4b32961414a9a0aa2b51
Autor:
Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James P. Buteau, Declan G. Murphy, Brian Kelly, Lavinia Spain, Shahneen Sandhu, Arun A. Azad, Elizabeth Medhurst, Grace Kong, Michael S. Hofman
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Reported here is a case of rapidly progressive metastatic castration-resistant prostate cancer treated with [ 177 Lu]Lu-PSMA-617 in the setting of severe renal impairment and impending ureteric obstruction. PSMA is expressed on renal tubular cells, r
Externí odkaz:
https://doaj.org/article/d046a9f4e7954988a4fbdf23c77fed17
Autor:
Muhammad Ali, Simon Wood, David Pryor, Daniel Moon, Mathias Bressel, Arun A. Azad, Catherine Mitchell, Declan Murphy, Homi Zargar, Nick Hardcastle, Jamie Kearsley, Renu Eapen, Lih Ming Wong, Katharine Cuff, Nathan Lawrentschuk, Paul J. Neeson, Shankar Siva
Publikováno v:
Contemporary Clinical Trials Communications, Vol 33, Iss , Pp 101145- (2023)
Background: Surgery remains the standard of care for localised renal cell carcinoma (RCC). Nevertheless, nearly 50% of patients with high-risk disease experience relapse after surgery, with distant sites being common. Considering improved outcomes in
Externí odkaz:
https://doaj.org/article/4d0e507036ae41018c85cc8e525fcedc
Autor:
Blossom Mak, Hui-Ming Lin, Edmond M. Kwan, Heidi Fettke, Ben Tran, Ian D. Davis, Kate Mahon, Martin R. Stockler, Karen Briscoe, Gavin Marx, Alison Zhang, Megan Crumbaker, Winston Tan, Kevin Huynh, Thomas G. Meikle, Natalie A. Mellett, Andrew J. Hoy, Pan Du, Jianjun Yu, Shidong Jia, Anthony M. Joshua, David J. Waugh, Lisa M. Butler, Manish Kohli, Peter J. Meikle, Arun A. Azad, Lisa G. Horvath
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-14 (2022)
Abstract Background Both changes in circulating lipids represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumour genetic aberrations are individually associated with worse clinical outcomes in men with metastatic castratio
Externí odkaz:
https://doaj.org/article/0c49ff062a1c4a14adec64ab46d60c0a
Autor:
Louise Kostos, James P. Buteau, Theresa Yeung, Juliana Di Iulio, Jing Xie, Anthony Cardin, Kwang Y. Chin, Brittany Emmerson, Katie L. Owen, Belinda S. Parker, Heidi Fettke, Luc Furic, Arun A. Azad, Michael S. Hofman
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Background[177Lu]Lu-PSMA is a radioligand therapy used in metastatic castration-resistant prostate cancer (mCRPC). Despite a survival benefit, the responses for many patients receiving [177Lu]Lu-PSMA are not durable, and all patients eventually devel
Externí odkaz:
https://doaj.org/article/ee75493d95874a12b67e6d0f0cb88f42
Autor:
Gail P. Risbridger, Ashlee K. Clark, Laura H. Porter, Roxanne Toivanen, Andrew Bakshi, Natalie L. Lister, David Pook, Carmel J. Pezaro, Shahneen Sandhu, Shivakumar Keerthikumar, Rosalia Quezada Urban, Melissa Papargiris, Jenna Kraska, Heather B. Madsen, Hong Wang, Michelle G. Richards, Birunthi Niranjan, Samantha O’Dea, Linda Teng, William Wheelahan, Zhuoer Li, Nicholas Choo, John F. Ouyang, Heather Thorne, Lisa Devereux, Rodney J. Hicks, Shomik Sengupta, Laurence Harewood, Mahesh Iddawala, Arun A. Azad, Jeremy Goad, Jeremy Grummet, John Kourambas, Edmond M. Kwan, Daniel Moon, Declan G. Murphy, John Pedersen, David Clouston, Sam Norden, Andrew Ryan, Luc Furic, David L. Goode, Mark Frydenberg, Mitchell G. Lawrence, Renea A. Taylor
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
The prognosis of castration-resistant prostate cancers remains dismal, but accurate preclinical models can lead to effective therapies. Here the Melbourne Urological Research Alliance establish prostate cancer patient-derived xenografts, use the tumo
Externí odkaz:
https://doaj.org/article/72ce33db9321419ba5cb98782c40a1e1
Autor:
Hui-Ming Lin, Blossom Mak, Nicole Yeung, Kevin Huynh, Thomas G. Meikle, Natalie A. Mellett, Edmond M. Kwan, Heidi Fettke, Ben Tran, Ian D. Davis, Kate L. Mahon, Alison Zhang, Martin R. Stockler, Karen Briscoe, Gavin Marx, Megan Crumbaker, Phillip D. Stricker, Pan Du, Jianjun Yu, Shidong Jia, Tahlia Scheinberg, Michael Fitzpatrick, Paul Bonnitcha, David R. Sullivan, Anthony M. Joshua, Arun A. Azad, Lisa M. Butler, Peter J. Meikle, Lisa G. Horvath
Publikováno v:
EBioMedicine, Vol 72, Iss , Pp 103625- (2021)
Background: Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 20–30% of men with metastatic castration-resistant prostate cancer (mCRPC). Ceramide metabolism may have a role in ARSI resistance. Our study's aim is to i
Externí odkaz:
https://doaj.org/article/9cf94dae05774bb884af7691d010665c